JonesTrading analyst Soumit Roy maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) today. The company’s shares opened today at $0.57.
Roy covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Oncolytics Biotech, and Cassava Sciences. According to TipRanks, Roy has an average return of -6.6% and a 25.81% success rate on recommended stocks.
Currently, the analyst consensus on Adaptimmune Therapeutics is a Moderate Buy with an average price target of $3.80.
See the top stocks recommended by analysts >>
ADAP market cap is currently $134.3M and has a P/E ratio of -1.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics (ADAP) Company Description:
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Read More on ADAP:
